{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:02:54Z","timestamp":1791770574894,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"RGC Postdoctoral Fellowship Scheme","award":["No. UGC\/GEN\/562\/3"],"award-info":[{"award-number":["No. UGC\/GEN\/562\/3"]}]},{"name":"RGC General Research Fund","award":["CUHK14122725"],"award-info":[{"award-number":["CUHK14122725"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82403017"],"award-info":[{"award-number":["No. 82403017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02163-x","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:54:51Z","timestamp":1778860491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies"],"prefix":"10.1007","volume":"26","author":[{"given":"Jialin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuda","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2163_CR1","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng ML, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S32\u201342. https:\/\/doi.org\/10.3350\/cmh.2022.0365.","journal-title":"Clin Mol Hepatol"},{"key":"2163_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW-S Wong","year":"2023","unstructured":"Wong VW-S, Ekstedt M, Wong GL-H, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036.","journal-title":"J Hepatol"},{"key":"2163_CR3","doi-asserted-by":"publisher","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81, 492\u2013542 (2024). https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2163_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-02024-9","volume":"17","author":"J Wu","year":"2025","unstructured":"Wu J, et al. Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023. Diabetol Metab Syndr. 2025;17:462. https:\/\/doi.org\/10.1186\/s13098-025-02024-9.","journal-title":"Diabetol Metab Syndr"},{"key":"2163_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"key":"2163_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101506","volume":"50","author":"J Bilson","year":"2024","unstructured":"Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50:101506. https:\/\/doi.org\/10.1016\/j.diabet.2023.101506.","journal-title":"Diabetes Metab"},{"key":"2163_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7570\/jomes22021","volume":"31","author":"Y Huh","year":"2022","unstructured":"Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. J Obes Metab Syndr. 2022;31:17\u201327. https:\/\/doi.org\/10.7570\/jomes22021.","journal-title":"J Obes Metab Syndr"},{"key":"2163_CR8","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32\u201350. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"key":"2163_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1.","journal-title":"Nat Rev Dis Primers"},{"key":"2163_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02616-9","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wu J, Li T, Qu Y, Wang Y. Association of triglyceride-glucose related indices with mortality among individuals with MASLD combined with prediabetes or diabetes. Cardiovasc Diabetol. 2025;24:52. https:\/\/doi.org\/10.1186\/s12933-025-02616-9.","journal-title":"Cardiovasc Diabetol"},{"key":"2163_CR11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/apt.70012","volume":"61","author":"KM Schneider","year":"2025","unstructured":"Schneider KM, et al. The lipidomic profile discriminates between MASLD and MetALD. Aliment Pharmacol Ther. 2025;61:1357\u201371. https:\/\/doi.org\/10.1111\/apt.70012.","journal-title":"Aliment Pharmacol Ther"},{"key":"2163_CR12","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.3748\/wjg.v29.i20.3168","volume":"29","author":"J-L Wu","year":"2023","unstructured":"Wu J-L, et al. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy. World J Gastroenterol. 2023;29:3168\u201384. https:\/\/doi.org\/10.3748\/wjg.v29.i20.3168.","journal-title":"World J Gastroenterol"},{"key":"2163_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03525-z","volume":"24","author":"Y Hong","year":"2024","unstructured":"Hong Y, et al. Novel non-HDLc\/HDLc ratio for predicting MASLD: a cross-sectional study in a Chinese health screening population. BMC Gastroenterol. 2024;24:439. https:\/\/doi.org\/10.1186\/s12876-024-03525-z.","journal-title":"BMC Gastroenterol"},{"key":"2163_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03190-2","volume":"24","author":"XM Li","year":"2024","unstructured":"Li XM, Liu SL, He YJ, Shu JC. Using new indices to predict metabolism dysfunction-associated fatty liver disease (MAFLD): analysis of the national health and nutrition examination survey database. BMC Gastroenterol. 2024;24:109. https:\/\/doi.org\/10.1186\/s12876-024-03190-2.","journal-title":"BMC Gastroenterol"},{"key":"2163_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26072959","author":"JE Mej\u00eda-Guzm\u00e1n","year":"2025","unstructured":"Mej\u00eda-Guzm\u00e1n JE, Belmont-Hern\u00e1ndez RA, Ch\u00e1vez-Tapia NC, Uribe M, Nu\u00f1o-L\u00e1mbarri N. Metabolic-dysfunction-associated steatotic liver disease: molecular mechanisms, clinical implications, and emerging therapeutic strategies. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26072959.","journal-title":"Int J Mol Sci"},{"key":"2163_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcancer.2023.04.010","volume":"93","author":"SA Polyzos","year":"2023","unstructured":"Polyzos SA, Chrysavgis L, Vachliotis ID, Chartampilas E, Cholongitas E. Nonalcoholic fatty liver disease and hepatocellular carcinoma: insights in epidemiology, pathogenesis, imaging, prevention and therapy. Semin Cancer Biol. 2023;93:20\u201335. https:\/\/doi.org\/10.1016\/j.semcancer.2023.04.010.","journal-title":"Semin Cancer Biol"},{"key":"2163_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat C-H, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 2018;155:629\u201347. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.083.","journal-title":"Gastroenterology"},{"key":"2163_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","volume":"16","author":"R Bened\u00e9-Ubieto","year":"2024","unstructured":"Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD). Gut Microbes. 2024;16:2331460. https:\/\/doi.org\/10.1080\/19490976.2024.2331460.","journal-title":"Gut Microbes"},{"key":"2163_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22:429\u201343. https:\/\/doi.org\/10.1038\/s41577-021-00639-3.","journal-title":"Nat Rev Immunol"},{"key":"2163_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03565-5","volume":"24","author":"C Tang","year":"2024","unstructured":"Tang C, et al. Association between the lymphocyte-to-high-density lipoprotein ratio and metabolic dysfunction-associated steatotic liver disease among US adults: a cross-sectional study from NHANES 2017 to 2020. BMC Gastroenterol. 2024;24:470. https:\/\/doi.org\/10.1186\/s12876-024-03565-5.","journal-title":"BMC Gastroenterol"},{"key":"2163_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12876-024-03394-6","volume":"24","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020. BMC Gastroenterol. 2024;24:300. https:\/\/doi.org\/10.1186\/s12876-024-03394-6.","journal-title":"BMC Gastroenterol"},{"key":"2163_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1415484","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Association of systemic immune biomarkers with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study of NHANES 2007-2018. Front Nutr. 2024;11:1415484. https:\/\/doi.org\/10.3389\/fnut.2024.1415484.","journal-title":"Front Nutr"},{"key":"2163_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03584-2","volume":"25","author":"L-Z Huang","year":"2025","unstructured":"Huang L-Z, et al. Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017-2020. BMC Gastroenterol. 2025;25:4. https:\/\/doi.org\/10.1186\/s12876-024-03584-2.","journal-title":"BMC Gastroenterol"},{"key":"2163_CR24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41591-018-0178-4","volume":"24","author":"CJ Lynch","year":"2018","unstructured":"Lynch CJ, Liston C. New machine-learning technologies for computer-aided diagnosis. Nat Med. 2018;24:1304\u20135. https:\/\/doi.org\/10.1038\/s41591-018-0178-4.","journal-title":"Nat Med"},{"key":"2163_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06387-5","volume":"23","author":"G Zhu","year":"2025","unstructured":"Zhu G, et al. Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics. J Transl Med. 2025;23:381. https:\/\/doi.org\/10.1186\/s12967-025-06387-5.","journal-title":"J Transl Med"},{"key":"2163_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16112","volume":"45","author":"W Wu","year":"2025","unstructured":"Wu W, Guo Y, Li Q, Jia C. Exploring the potential of large language models in identifying metabolic dysfunction-associated steatotic liver disease: a comparative study of non-invasive tests and artificial intelligence-generated responses. Liver Int. 2025;45:e16112. https:\/\/doi.org\/10.1111\/liv.16112.","journal-title":"Liver Int"},{"key":"2163_CR27","doi-asserted-by":"publisher","unstructured":"Agha R. et al. Revised Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) Guideline: An update for the age of Artificial Intelligence. Premier Journal of Science. 2025. https:\/\/doi.org\/10.70389\/PJS.100081","DOI":"10.70389\/PJS.100081"},{"key":"2163_CR28","unstructured":"Centers for Disease Control and Prevention: National Health and Nutrition Examination Survey (NHANES). Interviewer Procedure Manual. 2017-2020. [cited 2025 June]. Avaliable from: https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/public\/2017\/manuals\/2017_Interviewer_Procedures_Manual.pdf."},{"key":"2163_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/HEP.0000000000000023","volume":"77","author":"E Vilar-Gomez","year":"2023","unstructured":"Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Samala N, Chalasani N. CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. Hepatology. 2023;77:1241\u201352. https:\/\/doi.org\/10.1097\/HEP.0000000000000023.","journal-title":"Hepatology"},{"key":"2163_CR30","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659\u2013689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"2163_CR31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"2163_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"key":"2163_CR33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","volume":"137","author":"A Kotronen","year":"2009","unstructured":"Kotronen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865\u201372. https:\/\/doi.org\/10.1053\/j.gastro.2009.06.005.","journal-title":"Gastroenterology"},{"key":"2163_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.03.034","author":"MT Long","year":"2016","unstructured":"Long MT, et al. Development and validation of the Framingham Steatosis Index to identify persons with hepatic steatosis. Clin Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1016\/j.cgh.2016.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2163_CR35","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2022021","volume":"44","author":"S Yun","year":"2022","unstructured":"Yun S, Oh K. The Korea National Health and Nutrition Examination Survey data linked Cause of Death data. Epidemiol Health. 2022;44:e2022021. https:\/\/doi.org\/10.4178\/epih.e2022021.","journal-title":"Epidemiol Health"},{"key":"2163_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.03.024","author":"Y-C Hsu","year":"2016","unstructured":"Hsu Y-C, et al. Association between serum level of Hepatitis B Surface Antigen at end of Entecavir therapy and risk of relapse in E Antigen-negative patients. Clin Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1016\/j.cgh.2016.03.024.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2163_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"key":"2163_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/gutjnl-2025-336127","volume":"75","author":"Z Huo","year":"2026","unstructured":"Huo Z, et al. Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut. 2026;75:772\u201385. https:\/\/doi.org\/10.1136\/gutjnl-2025-336127.","journal-title":"Gut"},{"key":"2163_CR39","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/liv.16096","volume":"44","author":"Z Pan","year":"2024","unstructured":"Pan Z, Yilmaz Y, Al-Busafi SA, Eslam M. The MAFLD definition identifies three homogenous groups of patients. Liver Int. 2024;44:3287\u20139. https:\/\/doi.org\/10.1111\/liv.16096.","journal-title":"Liver Int"},{"key":"2163_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024;157:155937. https:\/\/doi.org\/10.1016\/j.metabol.2024.155937.","journal-title":"Metabolism"},{"issue":"Suppl 1","key":"2163_CR41","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1111\/apt.17866","volume":"59","author":"W-K Chan","year":"2024","unstructured":"Chan W-K, Petta S, Noureddin M, Goh GBB, Wong VW-S. Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity. Aliment Pharmacol Ther. 2024;59(Suppl 1):S23\u201340. https:\/\/doi.org\/10.1111\/apt.17866.","journal-title":"Aliment Pharmacol Ther"},{"key":"2163_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4678526","volume":"2020","author":"A S\u00e1nchez-Garc\u00eda","year":"2020","unstructured":"S\u00e1nchez-Garc\u00eda A, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol. 2020;2020:4678526. https:\/\/doi.org\/10.1155\/2020\/4678526.","journal-title":"Int J Endocrinol"},{"key":"2163_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/EJE-17-0883","volume":"178","author":"OY Bello-Chavolla","year":"2018","unstructured":"Bello-Chavolla OY, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018;178:533\u201344. https:\/\/doi.org\/10.1530\/EJE-17-0883.","journal-title":"Eur J Endocrinol"},{"key":"2163_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126420","author":"L De la Cruz-Color","year":"2024","unstructured":"De la Cruz-Color L, et al. Evidence that peripheral Leptin Resistance in omental adipose tissue and liver correlates with MASLD in humans. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25126420.","journal-title":"Int J Mol Sci"},{"key":"2163_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo T, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36:947\u201368. https:\/\/doi.org\/10.1016\/j.cmet.2024.04.006.","journal-title":"Cell Metab"},{"key":"2163_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01886-5","volume":"22","author":"B Yin","year":"2023","unstructured":"Yin B, et al. Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2023;22:157. https:\/\/doi.org\/10.1186\/s12933-023-01886-5.","journal-title":"Cardiovasc Diabetol"},{"key":"2163_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02716-6","volume":"24","author":"Z Song","year":"2025","unstructured":"Song Z, et al. Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study. Cardiovasc Diabetol. 2025;24:154. https:\/\/doi.org\/10.1186\/s12933-025-02716-6.","journal-title":"Cardiovasc Diabetol"},{"key":"2163_CR48","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.3748\/wjg.v28.i36.5364","volume":"28","author":"S-J Duan","year":"2022","unstructured":"Duan S-J, et al. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease. World J Gastroenterol. 2022;28:5364\u201379. https:\/\/doi.org\/10.3748\/wjg.v28.i36.5364.","journal-title":"World J Gastroenterol"},{"key":"2163_CR49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.tips.2024.05.004","volume":"45","author":"R Booijink","year":"2024","unstructured":"Booijink R, Ramachandran P, Bansal R. Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment. Trends Pharmacol Sci. 2024;45:614\u201327. https:\/\/doi.org\/10.1016\/j.tips.2024.05.004.","journal-title":"Trends Pharmacol Sci"},{"key":"2163_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/294278","volume":"2015","author":"M Shen","year":"2015","unstructured":"Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol. 2015;2015:294278. https:\/\/doi.org\/10.1155\/2015\/294278.","journal-title":"Int J Endocrinol"},{"key":"2163_CR51","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/ijo.2015.102","volume":"39","author":"RS Dakin","year":"2015","unstructured":"Dakin RS, Walker BR, Seckl JR, Hadoke PWF, Drake AJ. Estrogens protect male mice from obesity complications and influence glucocorticoid metabolism. Int J Obes (Lond). 2015;39:1539\u201347. https:\/\/doi.org\/10.1038\/ijo.2015.102.","journal-title":"Int J Obes (Lond)"},{"key":"2163_CR52","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1089\/neu.2022.0515","volume":"40","author":"K Matsuo","year":"2023","unstructured":"Matsuo K, et al. Machine learning to predict three types of outcomes after traumatic brain injury using data at admission: A multi-center study for development and validation. J Neurotrauma. 2023;40:1694\u2013706. https:\/\/doi.org\/10.1089\/neu.2022.0515.","journal-title":"J Neurotrauma"},{"key":"2163_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-025-00634-6","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang P. Development and validation of a new diagnostic prediction model for NAFLD based on machine learning algorithms in NHANES 2017-2020.3. Hormones Athens. 2025. https:\/\/doi.org\/10.1007\/s42000-025-00634-6.","journal-title":"Hormones Athens"},{"key":"2163_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10994-006-6226-1","volume":"63","author":"P Geurts","year":"2006","unstructured":"Geurts P, Ernst D, Wehenkel L. Extremely randomized trees. Mach Learn. 2006;63:3\u201342. https:\/\/doi.org\/10.1007\/s10994-006-6226-1.","journal-title":"Mach Learn"},{"key":"2163_CR55","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.puhe.2024.04.034","volume":"232","author":"SU Baek","year":"2024","unstructured":"Baek SU, Won JU, Lee YM, Yoon JH. Association between long working hours and metabolic dysfunction-associated steatotic liver disease: a nationwide population-based study in Korea. Public Health. 2024;232:188\u201394. https:\/\/doi.org\/10.1016\/j.puhe.2024.04.034.","journal-title":"Public Health"},{"key":"2163_CR56","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68:763\u201372. https:\/\/doi.org\/10.1002\/hep.29797.","journal-title":"Hepatology"},{"key":"2163_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.10.008","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell Metab. 2025. https:\/\/doi.org\/10.1016\/j.cmet.2024.10.008.","journal-title":"Cell Metab"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02163-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:17:01Z","timestamp":1783484221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2163"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02163-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Theother authors declare that they have no known competing financial interests or personalrelationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since the data adopted in this study were all publicly available data from the NHANES and KNHANES, all data related studies were approved by their respective ethical review committees and received written informed consent from patients. Therefore, this study does not need additional ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"257"}}